logo
AMD Stock Trades Higher Than Industry at 5.63X P/S: Hold or Fold?

AMD Stock Trades Higher Than Industry at 5.63X P/S: Hold or Fold?

Advanced Micro Devices AMD shares are currently overvalued, as suggested by its Value Score of D.
The stock is trading at a premium, with a forward 12-month Price/Sales of 5.63X compared with the industry's 3.60X.
Price/Sales (F12M)
AMD shares have lost 3.9% in the year-to-date period, underperforming the Zacks Computer and Technology sector's increase of 2.5% and the Zacks Computer – Integrated Systems industry's growth of 16.4%.
The underperformance can be attributed to increasing macroeconomic challenges and uncertainty, which are attributed to higher tariffs. Export controls on certain Instinct GPUs to China posed a regulatory challenge.
AMD Stock Performance
However, AMD is benefiting from its expanding portfolio, accretive acquisitions and rich partner base.
AMD Expands AI Reach With New MI350 GPUs and Key Partners
AMD is strengthening its footprint in the artificial intelligence (AI) market through an expanding portfolio. AMD recently introduced its comprehensive, end-to-end AI platform at the 2025 Advancing AI event, introducing the powerful Instinct MI350 Series GPUs with 4x generational AI compute gains.
The company also showcased its open, rack-scale AI infrastructure and ROCm 7 software stack, enabling scalable, energy-efficient AI deployment. Strategic partners like Meta Platforms META, OpenAI, Microsoft MSFT, and Oracle ORCL highlighted AMD's growing role in powering next-gen AI workloads.
Meta Platforms announced the broad deployment of AMD Instinct MI300X for Llama 3 and Llama 4 inference. Meta Platforms also expressed strong interest in the MI350 Series and is collaborating with AMD on future AI roadmaps, including the MI400 platform.
Microsoft also announced that AMD Instinct MI300X is powering both proprietary and open-source models in production on Microsoft Azure. The collaboration with Microsoft supports scalable AI workloads across the cloud.
Oracle Cloud Infrastructure is among the first to adopt AMD's open rack-scale AI infrastructure featuring the MI355X GPUs. Oracle is also building zettascale AI clusters using up to 131,072 MI355X GPUs to support large-scale AI workloads.
AMD Benefits From Expanding EPYC Portfolio
AMD's expanding EPYC portfolio has been noteworthy. The company's strong adoption of fifth-gen EPYC Turin processors and expanding Instinct AI accelerator deployments across hyperscalers and enterprises have also been major growth drivers for its success.
EPYC processors are now deployed by all top 10 telecom, aerospace, and semiconductor companies. These processors are also gaining momentum in automotive, manufacturing, and energy sectors.
Building on this momentum, the company recently announced that Nokia has adopted its fifth-gen EPYC 9005 Series processors for the Nokia Cloud Platform.
These processors will enhance performance per watt for containerized workloads, which are important to 5G Core, edge, and enterprise applications. This integration supports telecom networks in meeting rising data demands while improving energy efficiency and reducing environmental impact.
AMD is also benefiting from accretive acquisitions to strengthen its AI ecosystem and bridge the technological gap with NVIDIA in the race for AI dominance. Exiting first-quarter 2025, AMD completed its acquisition of ZT Systems, combining its leadership in systems and racks with AMD's powerful GPUs, CPUs, networking silicon, and open-source software to tap into the $500 billion data center AI accelerator market by 2028.
AMD's Q2 Guidance Unimpressive
Despite an expanding portfolio and a rich partner base, AMD is expected to be hurt by export restrictions on GPUs to China, which will be a headwind and stiff competition from NVIDIA.
AMD expects second-quarter 2025 revenues of $7.4 billion (+/-$300 million). At the mid-point of the revenue range, this represents year-over-year growth of approximately 27%. AMD expects approximately a $700 million reduction in second-quarter 2025 revenues due to halted MI308X shipments to China.
AMD's Earnings Estimates Trend Downward
The Zacks Consensus Estimate for AMD's second-quarter 2025 earnings is currently pegged at 56 cents per share, which has decreased 13.8% over the past 30 days, indicating a year-over-year decline of 18.84%.
The consensus mark for second-quarter 2025 revenues is pegged at $7.41 billion, indicating year-over-year growth of 27%.
Conclusion: Hold AMD Stock for Now
AMD's expanding portfolio, strategic acquisitions and rich partner base are expected to improve its top-line growth.
However, its near-term prospects are dull due to macroeconomic uncertainties and stiff competition, particularly from NVIDIA in the cloud data center and AI chip markets. The growing demand for custom AI chips, offered by companies like Broadcom, is increasing concerns over market share. Stretched valuation also remains a concern.
AMD currently has a Zacks Rank #3 (Hold), suggesting that it may be wise for investors to wait for a more favorable entry point to accumulate the stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Advanced Micro Devices, Inc. (AMD): Free Stock Analysis Report
Microsoft Corporation (MSFT): Free Stock Analysis Report
Oracle Corporation (ORCL): Free Stock Analysis Report
Meta Platforms, Inc. (META): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%

Globe and Mail

time21 minutes ago

  • Globe and Mail

Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%

Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings

Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio
Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio

Globe and Mail

time28 minutes ago

  • Globe and Mail

Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio

Bill Ackman is a billionaire hedge fund manager as CEO of Pershing Square Capital Management. Unlike many of his peers on Wall Street, Ackman primarily keeps a tightly concentrated portfolio, with Pershing Square owning only about 10 stocks at any given time. For the last couple of years, Pershing Square's most direct artificial intelligence (AI) investment has been a sizable position in Alphabet. Ackman has made it clear that its diversified ecosystem -- spanning internet search, cloud computing, advertising, cybersecurity, and more -- combined with an attractive valuation is what enticed Pershing Square to take a position in the "Magnificent Seven" member. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Well, just a few weeks ago, news broke that Pershing Square had recently initiated a position in another AI stock, Amazon (NASDAQ: AMZN). Ackman now joins Warren Buffett, whom he is known to admire, and Cathie Wood as prominent personalities on Wall Street who have exposure to Amazon, through their respective portfolios at Berkshire Hathaway and ARK Invest. Let's explore what makes Amazon such a compelling AI stock for the long haul. I'll break down some trends in the business and the company's valuation to help explain why Amazon has earned the approval of Ackman, Buffett, and Wood. Amazon has a compelling AI narrative and... Given how hot AI has become, investors may be challenged to identify which opportunities are best suited for long-term positions. What I mean by that is while semiconductor stocks or AI software businesses have risen in popularity over the last couple of years, it's hard to know which of these companies will continue to be a market leader in 10 years (or longer). To me, Amazon is like the business version of a Swiss Army knife. The company's core segments are e-commerce and cloud computing infrastructure via Amazon Web Services (AWS). But it also has a thriving advertising business and a growing subscription service (Amazon Prime), and it has even made some progress in the streaming and entertainment landscape. Similar to Alphabet, Amazon is uniquely positioned to stitch its various operating units together through more AI-powered services. In essence, by leveraging the power of AI, it can bolster both the consumer and enterprise sides of its business and make the platform increasingly sticky for its customers. ... the company's investments are already bearing fruit While the ideas above sound great in theory, let's explore how the business has performed over the last couple of years since it started investing aggressively in AI. The first headline-grabbing move it made in AI was its investment in OpenAI rival Anthropic. The thesis around this partnership was to train Anthropic's generative AI model on AWS -- essentially integrating the efficiency of large language models into the AWS platform. Anthropic also agreed to use Amazon's in-house Trainium and Inferentia chipsets, providing the company with a direct avenue to begin scaling up a new part of its existing hardware business. Since Anthropic joined forces with Amazon, AWS revenue has accelerated considerably. But more important, operating income from Amazon's cloud business has almost doubled! AMZN Cash from Operations (TTM) data by YCharts; TTM = trailing 12 months. When you consider that Amazon's AI-driven growth is primarily sourced through just the cloud business right now, it becomes clearer that the company can leverage its robust profitability to reinvest in other areas of its business and jump-start those, too. I think that comes into focus as Wall Street's consensus revenue and earnings estimates over the next few years suggest there is much more growth ahead. AMZN Revenue Estimates for Current Fiscal Year, data by YCharts; EPS = earnings per share. Is Amazon a buy right now? Like many of its peers in the technology sector, Amazon has enjoyed a bit of a roller coaster ride so far this year. Shares bottomed at roughly $167 in April, which is likely when Ackman pounced. I say that because Pershing Square's position in Amazon was not included in the company's form 13F filing for the first quarter (ended March 31). If you had bought the dip in Amazon when Ackman did, you would have paid around 27 times forward earnings. AMZN PE Ratio (Forward) data by YCharts; PE = price to earnings. Among the 70 analysts who cover the stock, 66 rate it as either a buy or strong buy. Furthermore, with an average price target of $239, Wall Street's estimates imply there is still some modest upside. While Amazon's valuation has expanded over the last month and a half, the company's long-run prospects and added AI-centric uses still make it a reasonable buy in my view. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, and Berkshire Hathaway. The Motley Fool has a disclosure policy.

Craig Izenstark Launches Scholarship to Support Future Leaders in Finance and Technology
Craig Izenstark Launches Scholarship to Support Future Leaders in Finance and Technology

Globe and Mail

timean hour ago

  • Globe and Mail

Craig Izenstark Launches Scholarship to Support Future Leaders in Finance and Technology

Boca Raton, Florida--(Newsfile Corp. - June 14, 2025) - In a commitment to empowering the next generation of financial and technology leaders, Craig Izenstark has launched the Craig Izenstark Scholarship, a new initiative designed to support high-achieving students pursuing careers in finance, economics, data science, and related fields. To view an enhanced version of this graphic, please visit: With a belief that access to education is the foundation for lasting innovation and leadership, the scholarship program offers financial assistance to students who demonstrate academic excellence, personal integrity, and a vision for creating positive change in their chosen industries. "I've been fortunate to build a career in finance, but I recognize that not every talented student has the same opportunities," said Craig Izenstark. "This scholarship is my way of helping to level the playing field and invest in individuals who will drive progress in the future." The Craig Izenstark Scholarship is open to students across the United States. Applicants are required to submit a short essay that highlights their goals, achievements, and how they plan to contribute meaningfully to their field of study or community. The winner will receive a $1,000 award to help support their educational journey. Beyond financial support, the scholarship reflects Izenstark's broader mission to promote ethical leadership, innovation, and education in today's fast-changing economy. He believes that mentorship, opportunity, and access to resources are key drivers of long-term impact. The scholarship has already drawn interest from aspiring students eager to share their stories and gain support for their academic ambitions. How to Apply Students can learn more about eligibility requirements and apply through the official website: The application deadline and details are available on the site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store